2022
Cardiac magnetic resonance for prophylactic implantable-cardioverter defibrillator therapy international study: prognostic value of cardiac magnetic resonance-derived right ventricular parameters substudy
Al’Aref S, Altibi A, Malkawi A, Mansour M, Baskaran L, Masri A, Rahmouni H, Abete R, Andreini D, Aquaro G, Barison A, Bogaert J, Camastra G, Carigi S, Carrabba N, Casavecchia G, Censi S, Cicala G, Conte E, De Cecco C, De Lazzari M, Di Giovine G, Di Roma M, Dobrovie M, Focardi M, Gaibazzi N, Gismondi A, Gravina M, Guglielmo M, Lanzillo C, Lombardi M, Lorenzoni V, Lozano-Torres J, Margonato D, Martini C, Marzo F, Masci P, Masi A, Memeo R, Moro C, Mushtaq S, Nese A, Palumbo A, Pavon A, Pedrotti P, Pepi M, Marra M, Pica S, Pradella S, Presicci C, Rabbat M, Raineri C, Rodriguez-Palomares J, Sbarbati S, Schoepf U, Squeri A, Sverzellati N, Symons R, Tat E, Timpani M, Todiere G, Valentini A, Varga-Szemes A, Volpe A, Fusini L, Guaricci A, Schwitter J, Pontone G. Cardiac magnetic resonance for prophylactic implantable-cardioverter defibrillator therapy international study: prognostic value of cardiac magnetic resonance-derived right ventricular parameters substudy. European Heart Journal - Cardiovascular Imaging 2022, 24: 472-482. PMID: 35792682, PMCID: PMC10029842, DOI: 10.1093/ehjci/jeac124.Peer-Reviewed Original ResearchConceptsRight ventricular systolic dysfunctionCardiac magnetic resonanceAll-cause mortalityPredictor of all-cause mortalityRV ejection fractionPrognostic valueEjection fractionSystolic dysfunctionHeart failureQuantitative assessment of RV functionMean left ventricular ejection fractionAssessment of RV functionBaseline cardiac magnetic resonanceRV systolic dysfunctionRV systolic functionMedian follow-upNormal renal functionVentricular systolic dysfunctionVentricular ejection fractionReduced ejection fractionKaplan-Meier curvesRV functionNYHA III/IVSystolic functionRenal dysfunction
2017
TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups—A meta-analysis of aggregate data
Vuong H, Altibi A, Duong U, Ngo H, Pham T, Chan A, Park C, Fung K, Hassell L. TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups—A meta-analysis of aggregate data. Critical Reviews In Oncology/Hematology 2017, 120: 1-9. PMID: 29198322, DOI: 10.1016/j.critrevonc.2017.09.013.Peer-Reviewed Original ResearchConceptsTelomerase reverse transcriptase promoter mutationTelomerase reverse transcriptaseIsocitrate dehydrogenase mutation statusProgression-free survivalTERT promoter mutationsIsocitrate dehydrogenase mutationPromoter mutationsIDH-mutantGlioma patientsOverall survivalTumor gradeMutation statusTelomerase reverse transcriptase mutationsAssociated with reduced OSGrade II/III tumorsWHO grade IIMeta-analysisIDH-wild typeInverse variance methodRandom-effects modelII/III tumorsTERT-mutIII tumorsPrognostic factorsPrognostic valueBRAF Mutation is Associated with an Improved Survival in Glioma—a Systematic Review and Meta-analysis
Vuong H, Altibi A, Duong U, Ngo H, Pham T, Fung K, Hassell L. BRAF Mutation is Associated with an Improved Survival in Glioma—a Systematic Review and Meta-analysis. Molecular Neurobiology 2017, 55: 3718-3724. PMID: 28534272, DOI: 10.1007/s12035-017-0599-y.Peer-Reviewed Original ResearchConceptsProgression-free survivalKaplan Meier curveOverall survivalBRAF V600EPrognostic valueBRAF mutationsGlioma patientsImproved survivalData of hazard ratioHazard ratioYoung adult gliomasImproved overall survivalMeta-analysisInverse variance methodLow grade gliomasVirtual Health LibraryPrognosis of glioma patientsRandom-effects modelPrognostic impactPrognostic factorsTumor gradeFavorable prognosisPatient ageAdult gliomasPooled HRA meta-analysis of prognostic roles of molecular markers in papillary thyroid carcinoma
Vuong H, Duong U, Altibi A, Ngo H, Pham T, Tran H, Gandolfi G, Hassell L. A meta-analysis of prognostic roles of molecular markers in papillary thyroid carcinoma. Endocrine Connections 2017, 6: r8-r17. PMID: 28219937, PMCID: PMC5424840, DOI: 10.1530/ec-17-0010.Peer-Reviewed Original ResearchDisease-specific survivalDisease-free survivalPapillary thyroid carcinomaKaplan-Meier curvesPromoter mutationsHazard ratioPrognostic roleThyroid carcinomaData of hazard ratioVirtual Health LibraryAssess patient prognosisPooled hazard ratioInverse variance methodConfidence intervalsPrognosis of PTC patientsPredicting patient outcomesVisual inspection of funnel plotsMeta-analysesInspection of funnel plotsRandom-effects modelPrognostic valuePTC patientsEgger's regression testRisk stratificationPatient prognosis